Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group
- PMID: 9798025
- DOI: 10.1086/514934
Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group
Abstract
In this prospective, multicenter, double-blind study, the efficacy of ciprofloxacin was compared with that of clarithromycin as therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) from whom a pretherapy pathogen was isolated; the efficacy was measured by the infection-free interval. Clinical and microbiological responses at the end of therapy were secondary efficacy variables. Patients randomly received either ciprofloxacin or clarithromycin (500 mg twice a day for 14 days). Three hundred seventy-six patients with acute exacerbations of chronic bronchitis were enrolled in the study of whom 234 had an ABECB. Clinical resolution was observed in 90% (89 of 99) of ciprofloxacin recipients and 82% (75 of 91) of clarithromycin recipients for whom efficacy could be evaluated. The median infection-free interval was 142 days for ciprofloxacin recipients and 51 days for clarithromycin recipients (P = .15). Bacteriologic eradication rates were 91% (86 of 95) for ciprofloxacin recipients and 77% (67 of 87) for clarithromycin recipients (P = .01). In summary, compared with clarithromycin, treatment of ABECB with ciprofloxacin was associated with a trend toward a longer infection-free interval and a statistically significantly higher bacteriologic eradication rate.
Comment in
-
The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis.Clin Infect Dis. 1999 Jun;28(6):1344-5. doi: 10.1086/517802. Clin Infect Dis. 1999. PMID: 10451195 No abstract available.
Similar articles
-
Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.Clin Infect Dis. 1998 Oct;27(4):722-9. doi: 10.1086/514930. Clin Infect Dis. 1998. PMID: 9798024 Clinical Trial.
-
Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group.Clin Ther. 1997 Sep-Oct;19(5):989-1001. doi: 10.1016/s0149-2918(97)80051-3. Clin Ther. 1997. PMID: 9385486 Clinical Trial.
-
Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.Clin Ther. 1999 Jun;21(6):954-65. doi: 10.1016/S0149-2918(99)80017-4. Clin Ther. 1999. PMID: 10440620 Clinical Trial.
-
Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis.Chest. 2005 Jun;127(6):2231-6. doi: 10.1378/chest.127.6.2231. Chest. 2005. PMID: 15947342 Review.
-
[Objectives for antibiotic therapy in acute exacerbations of chronic bronchitis].Presse Med. 2001 Oct 27;30(31 Pt 2):17-22. Presse Med. 2001. PMID: 11721486 Review. French.
Cited by
-
Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.Antimicrob Agents Chemother. 2006 Mar;50(3):893-8. doi: 10.1128/AAC.50.3.893-898.2006. Antimicrob Agents Chemother. 2006. PMID: 16495248 Free PMC article.
-
Prevention of exacerbations of COPD with pharmacotherapy.Eur Respir Rev. 2010 Jun;19(116):119-26. doi: 10.1183/09059180.00002810. Eur Respir Rev. 2010. PMID: 20956180 Free PMC article. Review.
-
Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.Antimicrob Agents Chemother. 2016 Jun 20;60(7):4151-8. doi: 10.1128/AAC.00301-16. Print 2016 Jul. Antimicrob Agents Chemother. 2016. PMID: 27139476 Free PMC article.
-
Acute bronchitis: state of the art diagnosis and therapy.Compr Ther. 2004 Spring;30(1):55-69. doi: 10.1007/s12019-004-0025-z. Compr Ther. 2004. PMID: 15162593 Free PMC article. Review.
-
Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy.Clin Ther. 2001 Mar;23(3):499-512. doi: 10.1016/s0149-2918(01)80053-9. Clin Ther. 2001. PMID: 11318083 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical